Few Asian-American women participate in cancer treatment trials, but little is known about the barriers involved ( 1 -3 ) . We conducted a pilot study with oncologists and Asian-American women to describe these barriers. Because trial participation is a complex process, we used the Pathways Model, a comprehensive framework that postulates that health-related behaviors require patients to negotiate a Community Pathway and providers a Medical Pathway, each with barriers and facilitating factors ( 4 -5 ) . The pathways interact through language and cultural concordance, system capacity, and patient education. We hypothesized that patients and physicians perceived different types of barriers, that both would identify language discordance as a barrier, and that Asian oncologists were more likely than non-Asians to identify barriers consistent with the patients' reports.
Few Asian-American women participate in cancer treatment trials, but little is known about the barriers involved ( 1 -3 ) . We conducted a pilot study with oncologists and Asian-American women to describe these barriers. Because trial participation is a complex process, we used the Pathways Model, a comprehensive framework that postulates that health-related behaviors require patients to negotiate a Community Pathway and providers a Medical Pathway, each with barriers and facilitating factors ( 4 -5 ) . The pathways interact through language and cultural concordance, system capacity, and patient education. We hypothesized that patients and physicians perceived different types of barriers, that both would identify language discordance as a barrier, and that Asian oncologists were more likely than non-Asians to identify barriers consistent with the patients' reports.
In 2003, using lists from the American Medical Association, the American Society of Clinical Oncologists, and hospitals (excluding Kaiser Permanente), we mailed anonymous surveys to all 132 medical oncologists in three Northern California counties. Items included sociodemographics, practice characteristics, proportion of Asian-American women with whom trials were discussed, and proportions of Asian-American women who were referred to and enrolled in trials. Using a 5-point scale, oncologists reported research attitudes, rated physician barriers, and assessed 23 barriers relevant to these women. Statistical analyses were performed using SAS (SAS Institute, Cary, NC).
Bilingual researchers conducted individual, face-to-face, semistructured interviews in Cantonese, English, or Vietnamese with 10 Chinese and 9 Vietnamese women with cancer from Northern California. The interviews were audiotaped, transcribed, and translated into English. Participants were asked whether they had heard of trials, whether trials were ever discussed, and whether they participated. Using openended questions followed by probes, the interviewer assessed research perceptions, attitudes, and barriers. Participants also rated 34 factors for their importance. Using standard techniques ( 6 -7 ) , two researchers independently coded transcripts using an iterative process and resolved differences by consensus.
Forty-four oncologists responded (response rate = 33.3%). Most had information about trials and had positive attitudes. The major Medical Pathway barriers included lack of staff, lack of time, effort to learn about trials, and eligibility criteria. Many (62.9%) had discussed trials with at least 5% of Asian-American women in the preceding 6 months.
Most Asian oncologists spoke an Asian language. Asian and non-Asian oncologists reported similar attitudes, physician barriers, and NCI trials behavior. More Asian than non-Asian oncologists had referred (75.0% vs. 9.5%, P ≤ .001) and enrolled (40.0% vs. 9.5%, P <.05) Asian-American women in industry trials.
Few oncologists thought that AsianAmericans were reluctant to participate or that physicians were not informing them about trials ( Table 1 ). The oncologists reported that the main barriers for Asian-American women were pathways interactions such as researcherparticipant language discordance, lack of culturally relevant cancer information, and complex protocols. Family decision making was the main Community Pathway barrier.
Signifi cantly more Asian than nonAsian oncologists chose as patient barriers lack of culturally relevant cancer information (64.3% vs. 32.1%) and fear of experimentation (50.0% vs. 20.7%) ( P <.05). Although not statistically signifi cant, more Asian oncologists chose lack of knowledge about research and family decision making as Community Pathway barriers.
All 19 patients were foreign born with ages ranging from 33 to 71 years. Most had limited English profi ciency. Few had oncologists who spoke Asian languages. Only four had heard of treatment trials ( Table 2 ). Fear of side effects was the main barrier to participation, followed by language problems, competing needs, and fear of experimentation or distrust. Family reluctance was also a prominent barrier. Many would consider participation if their physicians recommended it in a respectful manner.
Consistent with a prior study ( 3 ) , oncologists and patients agreed that language was a barrier to trial participation for Asian-American women. Language discordance affects physician -patient communication among Asian-Americans ( 8 -9 ) and research participation in other pop ulations ( 10 ) . In this study, Asian oncologists were more likely to speak an Asian language and to have enrolled Asian-American women in industry trials. This indicates that language and possibly cultural concordance can lead to more participation. However, many AsianAmerican women with cancer received care from non-Asian oncologists. To facilitate trial participation, these patients may need language and cultural support through interpreters or patient navigators.
An important factor identifi ed by both oncologists and patients but not in the literature was the family decision-making process, which is important in other Asian-American health behaviors ( 11 ) . Even non-Asian oncologists identifi ed this barrier, indicating that it is prevalent enough to be perceived by those from a different culture. This cultural factor deserves further investigation, but our fi nding indicates that family members should be involved in the discussion about trial participation.
Oncologists and patients disagreed on other barriers. Most oncologists reported trial discussion with these women, but similar to fi ndings in other groups, patients reported that they were not informed ( 12 , 13 -14 ) . Oncologists and patients also differed regarding willingness to participate. The women would participate only under dire circumstances. Their reluctance is more marked than that reported in other groups ( 15 -16 ) . This may be a result of lack of knowledge about cancer and the research process, as people who knew more were more willing to participate ( 16 ) . Distrust, a barrier among African Americans ( 12 , 17 ) , was reported by some Asian-American women but not by oncologists. Refl ecting the views of the patients, more Asian than non-Asian oncologists identifi ed as barriers lack of culturally relevant cancer information, fear of experimentation, and family decision making. As a result of having a shared background, Asian oncologists may have insight about barriers for Asian-American patients. Including ethnically concordant physicians in studies may lead to culturally appropriate interventions to increase participation ( 17 -18 ) .
Because of major limitations, the results of this pilot study are preliminary. The sampling frame and low response rate of the survey and the small number of foreign-born women interviewed limit the generalizability. Future studies could include physician -patient pairs to evaluate their interaction, and qualitative studies could evaluate cultural factors such as family decision making. Nonetheless, our fi ndings indicate that more oncologists should discuss treatment trials with Asian-American women and that studies of linguistically and culturally appropriate recruitment methods are needed. 
